Skip to content
DataLookout
Menu

ADVANCENCT07498335

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 18 → 23 locations
  2. Minor Trial sites expanded: 12 → 18 locations
  3. Notable Eligibility criteria expanded, about 40 words Show 5 more changesShow less
    • Trial sites expanded: 9 → 12 locations
    • Start date changed from estimate of Aug 26, 2026 to Aug 6, 2026
    • Secondary endpoints: details revised at 1 of 6 entries
    • Study description revised
    • Publications: details revised at 1 of 1 entry
  4. Minor Trial sites expanded: 6 → 9 locationsv7
  5. Notable Recruitment opened
    • Trial sites expanded: 2 → 6 locations
    v6
  6. Minor Study sites: 0 to 2v4
  7. Notable Primary completion pushed from Nov 29, 2030 to Sep 15, 2031
    • Study completion pushed from Jan 31, 2031 to Dec 13, 2032
    • Start date: Oct 2, 2026 to Aug 26, 2026
    v3
  8. Minor Publications: details revised at 1 of 1 entryv2
  9. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change From Baseline in Proteinuria at Week 36
Timeframe: Baseline and 36 weeks

Secondary (6)

Change from Baseline in Proteinuria at Week 36 in participants who experienced ≤ 30% decrease in proteinuria during the 60-day period prior to atrasentan initiation
PK parameters: Cmaxss
PK parameters: AUCss
PK parameters: CLss/F
PK parameters: Ctrough
Show 1 moreShow less
Number of participants with AEs

Arms and interventions

Cohort 1 (≥40 kg of body weight)Experimental

Once daily oral administration of 0.75 mg atrasentan for 104 weeks

Cohort 2 (30 to <40 kg of body weight)Experimental

Oral administration of weight-based appropriate dose(s) (that may be modified based on emerging data) for 104 weeks

Cohort 3 (20 to <30 kg of body weight)Experimental

Oral administration of weight-based appropriate dose(s) (that may be modified based on emerging data) for 104 weeks

Cohort 4 (10 to <20kg of body weight)Experimental

Oral administration of weight-based appropriate dose(s) (that may be modified based on emerging data) for 104 weeks

Drugs: Drug: Atrasentan

Sites

23 sites in 8 countries

France 4, Japan 4, Spain 4, United States 4, China 2, Colombia 2, Taiwan 2, South Korea 1